Reneo Pharma reports Q4 net loss $10.6M; cash $147.7M; no Phase 2 for McArdle

OnKure Therapeutics, Inc.

Net loss for Q4 2021 was $10.6M ($0.43 per share) vs $6.3M in Q4 2020; full year net loss $39.8M.
Cash, cash equivalents and short-term investments at Dec 31, 2021: $147.7M, sufficient into 2024.
STRIDE Phase 2b PMM study enrollment ongoing; data expected in 2023; LC-FAOD data in 2Q 2022.
REN001 in McArdle disease: no drug-related SAEs; company will not pursue Phase 2 for McArdle.
Appointed Ashley Hall as Chief Development Officer and Eric Dube to Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.